Compare Harley-Davidson Inc (HOG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs ResMed Inc. — how do they compare? Harley-Davidson Inc trades at $26.75 (market cap $2.80B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 11.3× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and ResMed Inc. for 51 Days on average.
| HOG | RMD | |
|---|---|---|
Market Cap | $2.80B | $31.78B |
Volume | 2,093,216 | 1,128,382 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $277.88 |
52-Week Low | $17.19 | $182.82 |
Typical Hold Time | 91 Days | 51 Days |
Enterprise Value | $3.22B | $31.14B |
Dividend Yield | 2.78% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.75, down 0.71% on the day, with a bullish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 14.97 and P/S of 0.72, but faces declining revenue and net income margins. Recent news highlights tariff exposure and a data breach, while analyst consensus is a 'Hold' with a $28.50 price target. Cash flow trends are volatile, with 2025 showing a net inflow of $1.35 billion driven by investing activities.
The outlook for HOG is cautious due to fundamental pressures, including falling profitability and revenue, offset by low valuations and a dividend. Key risks include competitive threats and sensitivity to tariffs. Upside potential exists if the 'Back to the Bricks' strategy revives growth, but investors should weigh margin erosion against valuation support.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
